April 26, 2026
Baby aspirin, big drama
Low-Dose Aspirin Usage for Primary Prevention Has Fallen by >50% Since 2018
Doctors drop daily 'baby aspirin' as comments split between science wins and stomach woes
TLDR: Daily low‑dose aspirin for first‑time heart attack or stroke prevention has plunged since 2018, as studies showed limited benefit and higher bleeding risk in older adults. Commenters split between applauding evidence‑based medicine and swapping gut‑injury horror stories, asking why many 80+ are still on it.
The internet is buzzing after new data showed daily low‑dose aspirin for preventing first-time heart attacks and strokes has fallen by more than half since 2018. Commenters are framing it as a comeback story for evidence: trials in 2018 showed the benefits were small and bleeding risks—especially for folks 75+—were bigger than expected, prompting new guidelines from ACC/AHA and the USPSTF. Herodotus38 cheers, calling it proof doctors can pivot when the science changes. But the top counter‑vibe? The gut talk. OutOfHere’s graphic warning about aspirin “wrecking the stomach” turned into a whole thread of digestive horror stories, with people declaring the “enteric‑coated” myth officially busted. Drama flared over older adults: despite the drop to 3.2% overall, ages 80+ still show 5.7% using it, even as bleeding risk in that group jumps 33–37%. Some applaud the slowdown; others worry grandpa’s “vitamin” habit is hard to break. Humor slipped in, too: “Baby aspirin isn’t so baby,” memes and “from daily habit to daily hazard” one‑liners rolled in. The biggest rift: evidence‑based U‑turn versus long‑held routines—one side chanting “trust the trials,” the other clutching their stomachs and saying “told you so.”
Key Points
- •Low-dose aspirin use for primary prevention decreased from 7.4% (mid‑2018) to 3.2% (end‑2025) across 279 million primary care encounters.
- •Declines were steady since 2018 and consistent across demographic subgroups; adults 80+ still had the highest prevalence (5.7% in late 2025).
- •Bleeding risk analysis of 625,742 first-time aspirin users found a 33% higher major bleeding risk in ages 75–79 and 37% higher in ages 80+ versus matched aspirin-allergy controls.
- •For adults under 75, differences in major bleeding risk between aspirin users and matched allergy controls were not statistically significant.
- •Guideline changes followed 2018 trials: 2019 ACC/AHA advised against routine use; 2022 USPSTF recommended against initiating aspirin in adults 60+.